CONICET | Buscador de Institutos y Recursos Humanos

RETINOIC ACID REDUCES MIGRATION OF HUMAN BREAST AND CERVICAL CANCER CELLSMartinez AL, Vanderhoeven F, Redondo AL, Vargas Roig LM, Sánchez AM and Flamini MI. Laboratorio de Biología Tumoral. IMBECU-CCT-CONICET-Mendoza, Argentina. E-mail: mflamini@mendoza-conicet.gov.arBreast and Cervical cancer are common malignant diseases worldwide. Retinoids are currently being used in clinical trials to treat or prevent cancer progression. We have previously demonstrated that long retinoic acid (RA) treatment (10-6M) reduced cellular adhesion and migration in breast cancer cells. In addition, we verified FAK/Paxillin and HSP27 nuclear translocation during 3-6 hours of RA treatment. As a consequence, we speculate that RA reduces breast cancer cell adhesion by inhibiting the formation of focal adhesion complexes and we hypothesize that FAK is carried by HSP27. The aims of this work were to verify in T47D breast cancer cells if HSP27 interacts with FAK/Paxillin, determine in HeLa cervical cancer cells if FAK/Paxillin are translocated to the nucleus after RA treatment and define if RA decreases the migration of HeLa cells. Immunofluorescence, western blot and migration assays were performed in HeLa 1.3 cells (with HSP27 expression) and HeLa 2.2 cells (without HSP27 expression). Additionally immunoprecipitation was used in T47D cells. We observed that FAK interacts with HSP27 in T47D cells and this interaction is increased after RA treatment. FAK translocates to the nucleus in HeLa 2.2 after RA treatment, suggesting that HSP27 is not essential in this process. Furthermore, RA treatment (10-5 M) decreases Hela 2.2 cells migration. We concluded that HSP27 has not a crucial role in the inhibition of cancer cells migration and FAK nuclear translocation induced by RA. Also, the highest concentration of RA (10-5 M) reduces cell migration in HeLa 2.2 cells.